34.10:
Abnormal Proliferation
Cells have special genes called tumor suppressor genes that can neutralize the effect of harmful genetic alterations and prevent uncontrolled cell proliferation.
For example, p53 is a tumor suppressor gene that maintains a basal level of expression under normal cell conditions.
Mdm2 protein acts as a negative regulator of p53 activity. It binds to the functional domain of p53 protein, reducing its transcriptional activity.
Mdm2 also exhibits p53-specific ubiquitin ligase activity and catalyzes the attachment of ubiquitin to p53. The polyubiquitinated p53 proteins are then recognized and degraded by the proteasome, maintaining it at extremely low levels inside the cell.
However, when the cells encounter abnormal conditions such as cellular stress or excessive mitogenic stimulation, the p53 gene is induced to enforce its tumor suppression activity.
For instance, overexpression of transcription factor Myc in the nucleolus triggers the accumulation of a tumor suppressor protein called- Arf.
Arf directly binds to Mdm2, inhibiting its ubiquitin ligase activity and sequestering it in the nucleolus, thus releasing active p53 into the nucleoplasm.
Active p53 then binds to specific DNA sequences and induces the expression of its target genes that can trigger accelerated DNA repair, arrest cell cycle, or induce cell apoptosis, thus, preventing further propagation of damaged cells.
However, when genetic or epigenetic changes alter p53 activity, it results in the collapse of the cell’s protective mechanisms. Such cells start proliferating aggressively and form tumors.
Besides, overexpression of Mdm2 is also frequently observed in liposarcomas. Although such tumors retain the normal p53 gene, the increased levels of Mdm2 keep p53 in an inactive state, hence, restricting their tumor suppression activity.
34.10:
Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter cells and all the future daughter cells. Such abnormal cell proliferation defines the characteristic of what we call cancer. The best example to explain this condition is the mutation in the Ras and MYC proteins.
Normal Ras proteins are GTPases that function in signal transduction from cell surface receptors to the cell’s interior. Ras proteins can be denoted as the binary switches that cycle between ON and OFF states during cellular growth. Usually, these switches are tightly regulated, but in Ras-related diseases such as cancer, the Ras gene mutation or their regulator renders Ras proteins persistently active. For instance, a single amino acid missense mutation in the K-Ras protein (a type of Ras protein) impairs its normal functioning. The mutant K-Ras cannot be inactivated, leading to continuous growth stimulation. K-Ras mutation occurs in 15%- 20% of human cancers, and is most commonly seen in colon cancer, lung cancer, pancreatic cancer, and leukemia.
Abnormal cell proliferation can also occur when mutation results in overexpression of MYC protein. The MYC oncogene belongs to a family of "super-transcription factors" and is deregulated in more than 50% of human cancers. The MYC affects a spectrum of cellular functions, including protein translation, cell cycle progression, ribosome biosynthesis, cell proliferation, differentiation, survival, and immune surveillance.
Suggested Reading
- Simanshu, Dhirendra K., Dwight V. Nissley, and Frank McCormick. "RAS proteins and their regulators in human disease." Cell 170, no. 1 (2017): 17-33.
- Chen, Hui, Hudan Liu, and Guoliang Qing. "Targeting oncogenic Myc as a strategy for cancer treatment." Signal transduction and targeted therapy 3, no. 1 (2018): 1-7.